Tenascin-C expression correlates with macrophage invasion in Duchenne muscular dystrophy and in myositis

Neuromuscular Disorders

Volumn 7, Issue 1, 1997, Pages 39-54

  Gullberg, Donald ^a   Velling, Teet ^a   Sjöberg, Gunnar ^b   Salmivirta, Katriina ^a   Gaggero, Barbara ^c   Tiger, Carl Fredrik ^a   Edström, Lars ^b   Sejersen, Thomas ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Becker muscular dystrophy; Duchenne muscular dystrophy; Extracellular matrix; Myogenesis; Myositis; Tenascin C

Indexed keywords

MONOCLONAL ANTIBODY; TENASCIN;

ARTICLE; BECKER MUSCULAR DYSTROPHY; DUCHENNE MUSCULAR DYSTROPHY; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MYOBLAST; MYOSITIS; PRIORITY JOURNAL;

EID: 0030902102     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(96)00391-4     Document Type: Article

References (51)

1. [1] Erickson HP. Tenascin-C. tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 1993:5:869-76.
2. [2] Chiquet ER. Tenascin and other adhesion-modulating proteins in cancer. Semin Cancer Biol 1993;4:301-10.
3. [3] Pearson CA, Pearson D, Shibahara S, Hofsteenge J, Chiquet-Erismann R. Tenascin: cDNA cloning and induction by TGF-β. EMBO J 1988;7:2977-81.
4. [4] Gulcher JR, Nies DE, Marton LS, Stefansson K. An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites. Proc Natl Acad Sci USA 1989:86:1588-92.
5. [5] Siri A, Carnemolla B, Saginati M, Leprini A, Casari G, Baralle F, Zardi L. Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucl Acid Res 1991;19:525-35.
6. [6] Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querze G, Zardi L. Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhes Commun 1994:1:307-17.
7. [7] Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Ann Rev Cell Biol 1989:5:71-92.
8. [8] Ekblom P, Aufderheide E. Stimulation of tenascin expression in embryonic mesenchyme by epithelial-mesenchymal interactions. Int J Dev Biol 1989:33:71-79.
9. [9] Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. J Cell Sci 1993;104:69-76.
10. [10] Tucker RP, Brunso BJ, Jenrath DA, Khan NA, Poss PM, Sweatt AJ, Xu Y. Cellular origins of tenascin in the developing nervous system. Perspect Dev Neurobiol 1994:2:89-99.
11. [11] Koukoulis GK, Howeedy AA, Korhonen M, Virtanen I, Gould VE. Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J Submicrosc Cytol Pathol 1993:25:285-95.
12. [12] Borsi L, Carnemolla B, Ponassi M, Zardi L. Steady-state levels of different tenascin mRNAs in various normal human tissues. Cell Biol Int 1993:17:325-29.
13. [13] Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986:47:131-39.
14. [14] Riou JF, Umbhauer M, Shi DL, Boucaut JC. Tenascin: a potential modulator of cell-extracellular matrix interactions during vertebrate embryogenesis. Biol Cell 1992;6:1-9.
15. [15] Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992;6:1821-31.
16. [16] Fernandez MS, Dennis JE, Drushel RF, Carrino DA, Kimata K, Yamagata M, Caplan AI. The dynamics of compartmentalization of embryonic muscle by extracellular matrix molecules. Dev Biol 1991;147:46-61.
17. [17] Glumoff V, Savontaus M, Vehanen J, Vuorio E. Analysis of aggrecan and tenascin gene expression in mouse skeletal tissues by northern and in situ hybridization using species specific cDNA probes. Biochim Biophys Acta 1994:1219:613-22.
18. [18] Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 1991;22:636-43.
19. [19] Whitby DJ, Longaker MT, Harrison MR, Adzick NS, Ferguson MW. Rapid epithelialisation of fetal wounds is associated with the early deposition of tenascin. J Cell Sci 1991;99:583-86.
20. [20] Natali PG, Nicotra MR, Bigotti A, Botti C, Castellani P, Risso AM, Zardi L. Comparative analysis of the expression of the extracellular matrix protein tenascin in normal fetal, adult and tumor tissues. Int J Cancer 1991:47:811-816.
21. [21] Brodkey JA, Laywell ED, O'Brien TF, Faissner A, Stefansson K, Dorries HU, Schachner M, Steindler DA. Focal brain injury and upregulation of a developmentally regulated extracellular matrix protein. J Neurosurg 1995;82:106-12.
22. [22] Gatchalian CL, Schachner M, Sanes JR, Fibroblasts that proliferate near denervated synaptic sites in skeletal muscle synthesize the adhesive molecules tenascin (J1). N-CAM, fibronectin, and a heparan sulfate proteoglycan. J Cell Biol 1989;108:1873-90.
23. [23] Irintchev A, Salvini TF, Faissner A, Wernig A. Differential expression of tenascin after denervation, damage or paralysis of mouse soleus muscle. J Neurocytol 1993;22:955-65.
24. [24] Hurme T, Kalimo H. Adhesion in skeletal muscle during regeneration. Muscle Nerve 1992;15:482-89.
25. [25] Jin P, Farmer K, Ringertz N, Sejersen T. Proliferation and differentiation of human fetal myoblasts is regulated by PDGF-BB. Differentiation 1993;54:47-54.
26. [26] Henriksson KG. 'Semi open' muscle biopsy technique. A simple outpatient procedure. Acta Neurol Scand 1979;59:317-23.
27. [27] Bourdon MA, Wiksrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983:43:2796-05.
28. [28] Poulter LW, Campbell DA, Munro C, Janossy G. Discrimination of human macrophages and dendritic cells by means of monoclonal antibodies. Scand J Immunol 1986;24:351-57.
29. [29] Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigott A, Natali PG. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989:108:1139-48.
30. [30] Balza E, Siri A, Ponassi M, Caocci F, Linnala A, Virtanen I, Zardi L. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 1993:332:39-43.
31. [31] Durbeej M, Söderström S, Ebendal T, Birchmeier C, Ekblom P. Differential expression of neutrophin receptors during renal development. Development 1993;119:977-89.
32. [32] Velling T. Characterization of three different monoclonal antibodies produced against cultured human fetal myogenic cells. Diploma work. Department of Animal Physiology. Uppsala University. 1994.
33. [33] Gullberg D, Sjöberg G, Velling T, Sejersen T. Analysis of fibronectin and vitronectin receptors on human fetal skeletal muscle cells upon differentiation. Exp Cell Res 1995;220:112-23.
34. [34] Mackie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol 1988:107:2757-67.
35. [35] Sjöberg G, Edström L, Lendahl U, Sejersen T. Myofibers from Duchenne Becker muscular dystrophy and myositis express the intermediate filament nestin. J Neuropathol Exp Neurol 1994:53:416-23.
36. [36] Campbell KP. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 1995:80:675-79.
37. [37] Worton R. Muscular dystrophies: diseases of the dystrophinglycoprotein complex. Science 1995;270:755-56.
38. [38] Rettig WJ, Erickson HP, Albino AP, Garin CP. Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. J Cell Sci 1994:107:487-97.
39. [39] Mackie EJ, Scott BT, Hahn AW, Kern F, Bernhardt J, Regenass S, Weller A, Buhler FR. Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol 1992;141:377-88.
40. [40] Umbhauer M, Riou JF, Spring J, Smith JC, Boucaut JC. Expression of tenascin mRNA in mesoderm during Xenopus lacvis embryogenesis: the potential role of mesoderm patterning in tenascin regionalization. Development 1992;116:147-57.
41. [41] McCachren SS, Lightner VA. Epression of human tenascin in synovitis and its regulation by interleukin-1. Artritis Rheum 1992;35:1185-96.
42. [42] Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L. Human tenascin gene. Structure of the 5′-region, identification, and characterization of the transcription regulatory sequences. J Biol Chem 1995;270:3429-34.
43. [43] Anderson JE, Liu L, Kardami E. Distinctive patterns of basic fibroblast growth factor (bFGF) distribution in degenerating and regenerating areas of dystrophic (mdx) striated muscles. Dev Biol 1991;147:96-109.
44. [44] Iannaccone S, Quattrini A, Smirne S, Sessa M, de Rino F, Ferini-Strambi L, Nemni R. Connective tissue proliferation and growth factors in animal models of Duchenne muscular dystrophy. J Neurol Sci 1995;128:36-44.
45. [45] Tidball JG, Spencer MJ, St Pierre BA. PDGF-receptor concentration is elevated in regenerative muscle fibers in dystrophin-deficient muscle. Exp Cell Res 1992;203:141-49.
46. [46] Settles DL, Cihac RA, Erickson HP. Tenascin-C expression in dystrophin-related muscular dystrophies. Muscle Nerve 1996;19:147-54.
47. [47] Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantification of T8 + cytotoxic and T8 + suppressor cells. Ann Neurol 1988;23:493-99.
48. [48] Langenfeld-Oster B, Faissner A, Irintchev A, Wernig A. Polyclonal antibodies against NCAM and tenascin delay endplate reinnervation. J Neurocytol 1994;23:591-604.
49. [49] Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-27.
50. [50] Yamada S, Ichida T, Matsuda Y et al. Tenascin expression in human chronic liver disease and in hepatocellular carcinoma. Liver 1992:12:10-16.
51. [51] Soini Y, Kamel D, Apajo-Sarkkinen M, Virtanen I, Lehto VP. Tenascin immunoreactivity in normal and pathological bone marrow. J Clin Pathol 1993:46:218-21.